We are live on !
Find out more
Alethea Capital Management Portfolio holdings
AUM
$241M
Turnover
72.09%
1-Year Est. Return
112.74%
This Fund
S&P 500
This Quarter Est. Return
+32.98%
1 Year Est. Return
+112.74%
3 Year Est. Return
+274.73%
5 Year Est. Return
+347.03%
10 Year Est. Return
+2,691.05%
AUM
$241M
AUM Growth
+$46.5M
(+24%)
Cap. Flow
+$716K
Cap. Flow % of AUM
Cap. Flow %
0.3%
Top 10 Holdings %
Top 10 Hldgs %
92.45%
Holding
43
New
29
Increased
2
Reduced
4
Closed
2
Avg Time Held
Equity + Options
0.9
years
Top 10 Avg Time Held
Equity + Options
2
years
Top 20 Avg Time Held
Equity + Options
1
year
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
2
years
Top 20 Avg Time Held Equity only
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kura Oncology
KURA
|
+$6.02M |
| 2 |
Immuneering
IMRX
|
+$2.28M |
| 3 |
Viatris
VTRS
|
+$1.21M |
| 4 |
Philip Morris
PM
|
+$1.19M |
| 5 |
Automatic Data Processing
ADP
|
+$1.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$28.9M |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$134K |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$124K |
| 4 |
Axsome Therapeutics
AXSM
|
+$77.6K |
| 5 |
WisdomTree Europe Hedged Equity Fund
HEDJ
|
+$14.7K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.57% |
| 2 | Miscellaneous | 13.25% |
| 3 | Consumer Staples | 1.81% |
| 4 | Energy | 1.45% |
| 5 | Technology | 1.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Axsome Therapeutics
AXSM
$7.57B
| $159M | 65.78% |
648,756
-358
| -0.1% | -$77.6K |
2017 Q4
34 quarters
|
|
|
2
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$51.2B
| $29.7M | 12.32% |
324,526
-315,512
| -49% | -$28.9M |
2024 Q1
9 quarters
|
|
|
3
Kura Oncology
KURA
$848M
| $23.8M | 9.85% |
2,167,938
+638,569
| +42% | +$6.02M |
2021 Q4
18 quarters
|
|
|
4
Immuneering
IMRX
$240M
| $2.36M | 0.98% |
472,935
+450,000
| +1,962% | +$2.28M |
2025 Q2
4 quarters
|
|
|
5
iShares 20+ Year Treasury Bond ETF
TLT
$48.9B
| $1.84M | 0.76% |
21,276
-1,555
| -7% | -$134K |
2021 Q4
18 quarters
|
|
6
Tempus AI
TEM
$12.3B
| $1.83M | 0.76% |
31,554
| – | – |
2025 Q4
2 quarters
|
|
|
7
Viatris
VTRS
$20.8B
| $1.24M | 0.52% |
+78,384
| New | +$1.21M |
2026 Q2
0 quarters
|
|
|
8
Philip Morris
PM
$312B
| $1.24M | 0.51% |
+6,834
| New | +$1.19M |
2026 Q2
0 quarters
|
|
|
9
Automatic Data Processing
ADP
$121B
| $1.23M | 0.51% |
+5,502
| New | +$1.18M |
2026 Q2
0 quarters
|
|
10
Williams Companies
WMB
$87.9B
| $1.14M | 0.47% |
+15,301
| New | +$1.13M |
2026 Q2
0 quarters
|
|
11
Darden Restaurants
DRI
$23.9B
| $1.12M | 0.46% |
+5,424
| New | +$1.09M |
2026 Q2
0 quarters
|
|
12
Bristol-Myers Squibb
BMY
$126B
| $1.09M | 0.45% |
+18,892
| New | +$1.08M |
2026 Q2
0 quarters
|
|
13
Consolidated Edison
ED
$42.7B
| $1.08M | 0.45% |
+9,767
| New | +$1.06M |
2026 Q2
0 quarters
|
|
14
Chevron
CVX
$458B
| $971K | 0.4% |
+5,860
| New | +$1.09M |
2026 Q2
0 quarters
|
|
15
Comcast
CMCSA
$80.8B
| $940K | 0.39% |
+38,283
| New | +$988K |
2026 Q2
0 quarters
|
|
16
Eversource Energy
ES
$25.4B
| $933K | 0.39% |
+12,915
| New | +$894K |
2026 Q2
0 quarters
|
|
17
Weyerhaeuser
WY
$14B
| $912K | 0.38% |
+38,100
| New | +$925K |
2026 Q2
0 quarters
|
|
18
Lockheed Martin
LMT
$140B
| $906K | 0.38% |
+1,778
| New | +$961K |
2026 Q2
0 quarters
|
|
19
AT&T
T
$142B
| $893K | 0.37% |
+43,146
| New | +$1.07M |
2026 Q2
0 quarters
|
|
20
Constellation Brands
STZ
$23.4B
| $847K | 0.35% |
+6,088
| New | +$905K |
2026 Q2
0 quarters
|
|
21
Broadridge
BR
$20.7B
| $840K | 0.35% |
+6,132
| New | +$926K |
2026 Q2
0 quarters
|
|
22
PNC Financial Services
PNC
$89.6B
| $801K | 0.33% |
+3,254
| New | +$729K |
2026 Q2
0 quarters
|
|
23
Hormel Foods
HRL
$11.6B
| $703K | 0.29% |
+28,344
| New | +$630K |
2026 Q2
0 quarters
|
|
24
ExxonMobil
XOM
$753B
| $602K | 0.25% |
+4,400
| New | +$659K |
2026 Q2
0 quarters
|
|
25
Atrium Therapeutics
RNA
$138M
| $589K | 0.24% |
43,758
| – | – |
2026 Q1
1 quarter
|
|
Similar funds
Alethea Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Alethea Capital Management held 43 positions worth $241M, up 24% from $195M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Alethea Capital Management's Q2 2026 filing shows 29 new, 2 increased, 4 reduced and 2 closed positions. Its largest new stake was Viatris: 78,384 shares worth $1.24M. The largest sale was State Street SPDR Bloomberg 1-3 Month T-Bill ETF, an estimated $28.9M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 64% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Alethea Capital Management's largest Q2 2026 buy was Viatris: 78,384 shares worth $1.24M.
- Alethea Capital Management added most to Kura Oncology in Q2 2026, an estimated $6.02M increase.
- Alethea Capital Management's biggest Q2 2026 reduction was State Street SPDR Bloomberg 1-3 Month T-Bill ETF, cutting an estimated $28.9M.
- Alethea Capital Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2026, selling an estimated $124K.
- Alethea Capital Management's ten largest holdings make up 92% of its $241M portfolio in Q2 2026.
- Alethea Capital Management opened 29 new positions and closed 2 in Q2 2026.
- Alethea Capital Management's portfolio value rose 24% quarter-over-quarter to $241M.
Based on Alethea Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.